ASH 2018 | Blinatumomab in combination with checkpoint inhibitors for ALL

Daniel DeAngelo

Daniel DeAngelo, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, discusses data for the combination of blinatumomab and nivolumab for relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia (Phase I; NCT02879695). Dr DeAngelo highlights the plan to extend this regimen to also include ipilimumab. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video